Nautilus Biotechnology

Nautilus Biotechnology, Inc. reports Q3 2024 earnings, beating expectations with an EPS of $-0.13 versus $-0.17 expected. The company discusses progress in proteomics, including advancements in single molecule protein analysis and proteoform detection, despite being behind on broad scale protein quantification milestones. Nautilus plans to focus on proteoform analysis in the first half of 2025, aiming for a commercial launch of its broad scale product in late 2025, with tight financial management to extend cash runway into 2027.

Nautilus Biotechnology co-founder and Chief Scientist Parag Mallick, Ph.D., awarded 2024 Distinguished Investigator Award by the Academy for Radiology and Biomedical Imaging Research for significant contributions to imaging research, including leadership, high-impact publications, and ongoing R&D work. Dr. Mallick to be inducted into the Academy's Council of Distinguished Investigators during the RSNA Annual Meeting in December 2024.

Suspicious activity violating TipRanks' Terms of Use detected, including excessive page views or use of bots. Account usually reactivates within 24 hours; contact support if still disabled.

Nautilus Biotechnology to participate in the Inaugural Guggenheim Healthcare Conference on Nov 13, 2024, at 9:30 a.m. Eastern Time. The event will feature a fireside chat, with a live and archived webcast available on the company's website.